Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. operates in Healthcare Service Provider, part of the Healthcare sector. It booked ₹798 cr of revenue in its latest quarter (Q1 FY27) and kept 21.2% of sales as profit. It is the largest of 9 Healthcare Service Provider companies we track, by market value.
“Statutory Reports Financial Statements Behind every one of these milestones is a conviction that has defined this organisation for over 75 years: that when diagnostics is done with genuine precision, it does not just inform treatment, it changes lives. The future of diagnostics is not a distant ambition.”
Healthier than 75% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 81–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 59
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in LALPATHLAB?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 4%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹798 cr |
| Other Income | ₹32 cr |
| Total Income | ₹830 cr |
| Cost of Materials | ₹152 cr |
| Purchases of Stock-in-Trade | ₹0 cr |
| Employee Benefit Expense | ₹133 cr |
| Finance Costs | ₹6 cr |
| Depreciation & Amortisation | ₹44 cr |
| Other Expenses | ₹266 cr |
| Total Expenses | ₹601 cr |
| Profit before Tax | ₹229 cr |
| Tax Expense | ₹58 cr |
| Net Profit | ₹171 cr |
| Net margin on total income | 20.6% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 660 cr | 703 cr | 798 cr |
| Total income | 684 cr | 727 cr | 830 cr |
| Expenses | 530 cr | 567 cr | 601 cr |
| Profit before tax | 124 cr | 160 cr | 229 cr |
| Tax | 33 cr | 28 cr | 58 cr |
| Net profit (owners' share) | 91 cr | 131 cr | 170 cr |
| Net margin (owners' share, on revenue) | 13.7% | 18.7% | 21.2% |
| EPS (₹) | 5.42 | 7.86 | 10.15 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd.this company | ₹1,925 | ₹32,258 cr | 47.4 | 27.0% | 21.2% | — |
| Vijaya Diagnostic Centre Limited | ₹1,506 | ₹15,497 cr | 73.0 | 22.2% | 23.0% | — |
| Metropolis Healthcare Limited | ₹586 | ₹12,156 cr | 53.7 | 15.0% | 12.6% | — |
| Thyrocare Technologies Limited | ₹559 | ₹8,902 cr | 43.3 | 35.7% | 21.7% | — |
| Nephrocare Health Services Limited | ₹735 | ₹7,376 cr | 57.6 | 11.5% | 11.3% | — |
| Krsnaa Diagnostics Limited | ₹541 | ₹1,755 cr | 26.5 | 6.8% | 7.0% | — |
| Suraksha Diagnostic Limited | ₹329 | ₹1,713 cr | 32.9 | 21.3% | 14.8% | — |
| Health X Platform Limited | ₹300 | ₹954 cr | 93.8 | 1.6% | 0.6% | — |
| Gaudium IVF and Women Health Limited | ₹115 | ₹836 cr | 114.8 | 4.7% | 9.2% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹5 / share | 30 Jul 2026 |
| Dividend | ₹4 / share | 25 Jun 2026 |
| Dividend | ₹3.5 / share | 5 Feb 2026 |
| Bonus issue | 1:1 | 19 Dec 2025 |
| Dividend | ₹7 / share | 7 Nov 2025 |
| Dividend | ₹6 / share | 6 Aug 2025 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 20 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.